Diagnosis and management of the hepatitis B reactivation in patients receiving cytotoxic chemotherapy

Abstract

Abstract: Nearly one third of the world's population have been infected with hepatitis B and the virus is endemic in many Asian countries. China has a high prevalence of HBV, and the number of chronic carriers reaches to ninety-three million. Chemotherapy is an important component in comprehensive treatment of tumor and with increasing life expectancy and the expected global increase in cancer, chemotherapy induced reactivation of HBV is likely to become an increasing problem. Severe liver damage causing by HBV reactivation may also result in a delay to complete chemotherapy or even death of liver failure. It has been recognized that HBV reactivation following chemotherapy can effectively be prevented by nucleoside analogue. However, the optimal method of prevention and treatment have not been fully clarified.

Key words: HBV, reactivation, chemotherapy, nucleoside analogue, liver failure

CLC Number:

R730.5

SUN De-cong, CHEN Li, WU Zhi-yong, DAI Guang-hai. Diagnosis and management of the hepatitis B reactivation in patients receiving cytotoxic chemotherapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(5): 584-590.

References

[1] Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research[J]. Hepatol Int,2008,2(2):152-162.
[2] Ikeda M. Reactivation of Hepatitis B Virus in Patients Receiving Chemotherapy[J]. Jpn J Clin Oncol,2013,43(1):8-16.
[3] Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy[J]. Gastroenterology, 2006, 131(1):59-68.
[4] Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab[J]. J Clin Onco,2009,27(4):605-611.
[5] Kusumoto S, Tanaka Y, Mizokami M, et al. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma[J]. Int J Hematol,2009,90(1):13-23.
[6] Hoofnagle JH. Reactivation of hepatitis B[J]. Hepatology,2009,49(5 Suppl):S156-165.
[7] Wursthorn K, Wedemeyer H, Manns MP. Managing HBV in patients with impaired immunity[J]. Gut,2010,59(10):1430-1445.
[8] Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy[J]. J Clin Oncol,2004,22(5):927-934.
[9] Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, et al. Anti-HBs positive occult hepatis B virus carrier blood infectious in two transfusion recipients[J]. J Hepatol,2008,48(6):1022-1025.
[10] Umemura T, Tanaka E, Kiyosawa K, et al. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan[J]. Clin Infect Dis,2008,47(5):e52-e56.
[11] Koo YX, Tan DS, Tan IB, et al. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy[J]. Cancer,2010,116(1):115-121.
[12] Koo YX, Tay M, Teh YE, et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis[J]. Ann Hematol,2011,90(10):1219-1223.
[13] Hui CK, Bowden S, Jackson K, et al. Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy[J]. Blood,2005,105(6):2616-2617.
[14] Wang DK, Tanaka Y, Lai CL, et al. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection[J]. J Clin Microbiol,2007,45(12):3942-3947.
[15] Kusumoto S, Tanaka Y, Ueda R, et al. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy[J]. J Gastroenterol,2011,46(1):9-16.
[16] Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factorsassociating with Hepatitis B virus (HBV) reactivation in cancerpatients undergoing cytotoxic chemotherapy[J]. Br J Cancer,2004,90(7):1306-1311.
[17] Zhong S, Yeo W, Schroder C, et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy[J]. J Viral Hepat,2004,11(1):55-59.
[18] Hui CK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy[J]. Gut,2005,54(11):1597-1603.
[19] Pei SN, Ma MC, Wang MC, et al. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy[J]. Ann Hematol,2012,91(7):1007-1012.
[20] Borentain P, Colson P, Coso D, et al. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer[J]. J Viral Hepat,2010,17(11):807-815.
[21] Hwang JP, Vierling JM, Zelenetz AD, et al. Hepatitis B virus management to prevent reactivation after chemotherapy: a review[J].Support Care Cancer,2012,20(11):2999-3008.
[22] Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: Diagnosis and management[J]. J Gastroenterol Hepatol,2010,25(5):864-871.
[23] Yun J, Kim KH, Kang ES, et al. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy[J].Br J Cancer,2011,104(4):559-563.
[24] Jang JW, Choi JY, Bae SH, et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma[J]. J Hepatol,2004,41(3):427-435.
[25] Cheng AL, Hsiung CA, Su IJ, et al. Lymphoma Committee of Taiwan Cooperative Oncology Group. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma[J]. Hepatology,2003,37(6):1320-1328.
[26] Wasmuth JC, Fischer HP, Sauerbruch T, et al. Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin's lymphoma[J].Eur J Med Res,2008,13(10):483-486.
[27] Tapan U, May SK, Fiore J, et al. Reactivation of hepatitis B virus following bendamustine-containing chemotherapy in a patient with multiple myeloma[J]. Leuk Lymphoma,2011,52(5):916-918.
[28] Wang LJ, Cai JT, Chen T, et al. The effects of Helicobacter pylori infection on hyperammonaemia and hepatic encephalopathy in cirrhotic patients[J]. Zhonghua Nei Ke Za Zhi,2006,45(8):654-657.
[29] Hsu C, Hsiung CA, Su IJ et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial[J]. Hepatology,2008,47(3):844-853.
[30] Lok AS, McMahon BJ. Chronic hepatitis B: update 2009[J]. Hepatology,2009,50(3):661-662.
[31] Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy[J]. Gastroenterology,2003,125(6):1742-1749.
[32] Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis[J]. Liver Int,2008,28(1):28-38.
[33] Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy[J]. Ann Intern Med,2008,148(7):519-528.
[34] Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific Consensus statement on the management of chronic hepatitis B: A 2012 update[J].Hepatol Int,2012,6(3):531-561.
[35] Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection[J]. MMWR Recomm Rep,2008,57(RR-8):1-20.
[36] Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B[J]. Aliment Pharmacol Ther,2011,34(10):1145-1158.
[37] Shamliyan TA, Johnson JR, MacDonald R, et al. Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection[J]. J Gen Intern Med,2011,26(3):326-339.
[38] Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B[J]. Gastroenterology,2003,125(6):1714-1722.
[39] Brost S, Schnitzler P, Stremmel W, et al. Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients[J]. World J Gastroenterol,2010,16(43):5447-5451.
[40] Li HR, Huang JJ, Guo HQ, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy[J]. J Viral Hepat,2011,18(12):877-883.
[41] 邹明智. 恩替卡韦与阿德福韦酯抑制乙型肝炎调节性T 细胞的效价差异[J]. 中国临床药理学与治疗学, 2011,16( 6) : 661- 665.
[42] Watanabe M, Shibuya A, Takada J, et al. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients[J]. Eur J Intern Med,2010,21(4):333-337.
[43] 贾继东,李兰娟. 慢性乙型肝炎防治指南(2010年)[J]. 中华肝脏病杂志, 2011,19(1):13-24.
[44] Matsumoto A, Tanaka E, Suzuki Y, et al. Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B[J]. Hepatol Res,2012,42(2):139-149.
[45] European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B[J]. J Hepatol,2009,50(2):227-242.